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Abstract—In this paper, a microwave non-invasive blood glu-
cose monitoring system operating at around 1.4 GHz is designed 
and its performance in terms of accuracy and repeatability is eval-
uated by a clinical trial involving 24 human subjects, with and 
without diabetes. Direct comparison with the most accurate 
benchtop glucose analyzer shows the exceptional accuracy and re-
peatability of the proposed system.  
Index Terms—Clinical trial, blood glucose, microwave, non-in-
vasive, wearable sensors. 
I. INTRODUCTION
Diabetes represents one of the largest health concerns of the 
21st century. It affects 7% of the world’s population and is on 
the rapid rise, being estimated to affect 1 in 10 adults by 2040 
[1]. The risk of diabetes-related complications can be signifi-
cantly reduced by maintaining tight control over blood glucose. 
At present many patients make regular measurements of their 
blood glucose. This usually involves withdrawing a blood sam-
ple via an invasive finger-prick procedure. This is both painful 
and inconvenient, resulting in reduced patient compliance and 
less effective glycemic control, or by other invasive methods, 
such as continuous glucose monitoring systems (CGMs), with 
associated risk of infection. As a result, there is an ever-growing 
demand for a reliable non-invasive glucose monitoring system. 
Various types of minimally or non-invasive blood glucose 
monitor (NIBGM) devices have been investigated across the 
full range of the electromagnetic spectrum, including radio 
waves, microwaves (GHz to THz range), infrared and visible 
radiation. In the radio and microwave range, near-field moni-
toring techniques have been widely used in the non-invasive 
characterization of material dielectric properties. Some exam-
ples include coplanar waveguide sensor integrated with micro-
fluidic system [2], a spiral-shaped microstrip transmission line 
sensor [3], microstrip patch/slot antenna-based sensor [4][5], 
and millimeter-wave waveguide transmission measurement 
system [6]. There are many reported results showing that the 
complex dielectric constant changes with the presence and fluc-
tuation of blood glucose concentration in the water/glucose sys-
tem and in humans [7][8]. In [9], we have shown that the pro-
totype microwave NIBGM sensor is effective in monitoring the 
fluctuation of blood glucose level in a laboratory environment.  
In this paper, a new non-invasive blood glucose monitoring 
system (NIBGM) is designed, and to evaluate the performance   
(a) (b)
Fig. 1. Photographs of the (a) proposed microwave non-invasive blood glu-
cose monitoring system, and (b) setup on a medical trolley for clinical trial. 
of the proposed NIBGM system, a human clinical trial involv-
ing 24 non-diabetic and diabetic subjects has been designed and 
carried out, and the results are presented. 
II. SYSTEM DESIGN AND DATA ANALYSIS
A. System Design
The basic experimental system consists of four elements as
shown in Fig. 1 (a), a sensor head, a portable vector network 
analyzer (VNA, N9923A, Keysight Technologies), a data log-
ger (NI 9219 CompactDAQ, National Instruments), and a PC 
with control software (LabVIEW, National Instruments). The 
VNA applies a swept frequency signal with an output power of 
about 1 mW to the sensor head and also measures the transmit-
ted power. The changes in resonant frequency, 3 dB bandwidth, 
and insertion loss are tracked in real-time by fitting to a skewed 
Lorentzian function. The system is set to produce data points 
every 2 seconds.  
The proposed NIBGM system measures the dielectric prop-
erties of the top few mm of epidermis, dermis and subcutaneous 
tissue in the abdominal area. As shown in Fig. 2 (a) in more 
detail, the sensor head is a microwave resonant circuit based on 
a split-ring resonator. The radius of the ring is 12 mm, and has 
a gap of 1 mm on one side, giving a resonant frequency of 
around 1.4 GHz. The ring is supported by perfluoroalkoxy al-
kane discs (PFA, Goodfellow) which have very low microwave 
loss, where the thickness of the discs are used to adjust the dis-
tance of the ring from human skin to optimize sensitivity and  
978-1-5090-6360-4/17/$31.00 ©2017 IEEE
 
(a) 
 
(b) 
Fig. 2. (a) 3D drawing of the wearable microwave sensor head. Overall di-
mensions are 44 x 60 x 12 mm3, and (b) illustration showing how the sensor is 
attached to human skin with open face facing towards skin for sensing. 
the dielectric loading effect. The specific parameters of the res-
onant circuit (its resonant frequency and bandwidth) are af-
fected by the dielectric properties of the tissues within its vicin-
ity. The ring resonator is enclosed in an aluminum case with 
one face open, where it is attached to the human skin via an 
adhesive dressing (1504XL, 3M) as shown in Fig. 2 (b). There-
fore there is no interference from external and ambient wireless 
signals, and also no microwave signal is radiated from the alu-
minum case. A temperature monitoring element, a thermistor, 
is also placed in the sensor head to monitor the fluctuation of 
skin temperature. The overall dimensions of the sensor head are 
44 x 60 x 12 mm3. It is connected to the VNA by lightweight 
and flexible microwave cables (Multiflex, Huber and Suhner). 
Two identical sensor units have been fabricated (labelled units 
1 and 2) for the clinical trial. Sensor performance evaluation 
including resonant characteristics, equivalent circuit models 
and finite element simulation model, and some interference test 
results can be found in [9]. 
B. Data Analysis  
Microwave data obtained from the VNA and the temperature 
data obtained from the data logger are synchronized and com-
bined with a time stamp derived from the system time to pro-
duce an output data file. Raw microwave data are temperature 
calibrated in this step. Around 450 microwave data points col-
lected over 15 minutes are averaged and this is synchronized to 
the time stamp on the blood glucose data. Reference blood glu-
cose values are measured at intervals of 15 minutes, as de-
scribed in the next section. Averaged microwave data readings 
are extracted at the same timings as for the blood glucose meas-
urements. Microwave data are converted to the estimated blood 
glucose concentration by using subject-specific linear correla-
tion coefficient calculated by the glucose concentration before 
and after glucose uptake. These two sets of values are plotted 
on the same graph using the same time base (time domain 
graph) and versus each other (correlation chart).  
The strength and direction of the correlation between micro-
wave readings (candidate method) and the reference blood glu-
cose values (comparative method) are quantified by using Pear-
son’s linear correlation coefficient R, and the accuracy is vali-
dated by mean absolute relative difference (MARD), which is 
defined as 
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where ܩప෡  is a blood glucose concentration estimated by the can-
didate method, ܩ௜ is a reference blood glucose concentration 
measured by the comparative method, and N is the number of 
samples. MARD is one of the most widely used figures when 
evaluating and comparing accuracy. Both Clarke Error Grid 
and Parkes Error Grid are also widely accepted as means of vis-
ualizing the accuracy of a device, where each zone on the grids 
has a certain clinical importance [10].   
III. CLINICAL TRIAL AND RESULTS 
A. Study Protocol 
An approval for a clinical trial was obtained from the UK 
Medicines and Healthcare products Regulatory Agency 
(MHRA) before commencing subject recruitment. People with 
the following conditions were excluded from the recruitment of 
the test subjects: evidence of clinically relevant disease, known 
hematological diseases or hemoglobin <12 g/dL, pacemaker, 
pregnancy. A single center study involving 24 subjects with and 
without diabetes was designed and carried out with 8 non-dia-
betic and 16 diabetic subjects (4 of type 1 and 12 of type 2).  
On each day of the study, after an overnight fast, each subject 
attended for a period of approximately 5 hours during which 
blood samples were taken for measurement using a conven-
tional laboratory glucose analyzer (YSI 2300 Glucose and Lac-
tate Analyzer), to compare with the NIBGM. Subjects con-
sumed a 75 g oral glucose drink in order that fasting and post-
prandial blood glucose samples could be measured over a wide 
range of blood glucose concentrations (typically 70 to 450 
mg/dL). No adverse effects were reported. During the pre-sam-
pling period on each day of the study, each subject was fitted 
with an indwelling cannula, sited into an antecubital fossa vein 
in the subject’s forearm in order to take samples throughout the 
study period. The cannula was attached via a three way tap to 
slow running saline (0.154 nmol/L) infusion to maintain the pa-
tency of the vein. The NIBGM sensor was then fixed securely 
to an abdomen site below the ribcage, using the 3M adhesive. 
Each sensor was warmed to 33 oC prior to body fixing to ensure 
that the time for them to reach thermal equilibrium with the 
subject’s body was minimized. Blood samples (1 mL each) 
were taken every 15 minutes with a time stamp over the course 
of 3 hours. Subjects continued to take their usual medication 
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throughout the study period. Subjects were allowed to walk 
around, although the range was quite limited due to the medical 
trolley, as shown in Fig. 1 (b).  
B. Results 
Fig. 3 shows oral glucose tolerance test results of one of the 
test subjects, plotted as a function of time and compared with 
the reference blood glucose concentration. It is clear to see that 
the estimated glucose concentration by the proposed NIBGM 
system matches well the rate of increase of glucose concentra-
tion after the glucose intake at t = 60 min. It is worth noting that 
there is no time delay between the two measurements, which 
proves that the proposed microwave NIBGM sensor penetrates 
deep enough into the skin and directly interacts with blood. To 
evaluate the correlation between the two measurements, the 
same data are plotted as a scatter chart and shown in Fig. 4. The 
linear correlation coefficient is 0.98 and the MARD of this spe-
cific data set is only 3.2%, which shows exceptional accuracy 
of the proposed measurement. To prove the repeatability, all the 
data from 24 subjects are plotted in a Clarke Error Grid and 
shown in Fig. 5. Most of the data are scattered in zones A and 
B, and only 4 points out of 214 points exist in zone C, with no 
data lying in zones D and E at all. The data points in zone C and 
near the zone B-C boundary are due to unexpected movement 
of some test subjects (when going to toilet, etc.). Table I sum-
marizes the MARD performance for all 24 subjects (12.5%), 12 
subjects measured by sensor unit 1 (11.0%), and the remaining 
12 subjects measured by sensor unit 2 (14.0%). This shows that 
there are device-to-device variations, possibly due to the hand-
built components and physiological difference between the test 
subjects.  
 
TABLE I 
MEAN ABSOLUTE RELATIVE DIFFERENCE ANALYSIS 
All 24 subjects 12 subjects by unit 1 12 subjects by unit 2 
12.5 % 11.0 % 14.0 % 
IV. CONCLUSION 
The efficacy of the proposed microwave NIBGM system was 
evaluated by a human clinical trial involving 24 healthy and di-
abetic subjects. The error grid and MARD results look very 
promising but the current system is quite restrictive in its use in 
that it involves the use of portable network analyzer and is not 
fully wearable/portable. Our future work is to integrate the pro-
posed system into a fully wearable sensor.  
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Fig. 3. Oral glucose tolerance test results of subject 18 (type 2), plotted as 
a function of time and compared with the blood glucose measured at the same 
time using a laboratory glucose analyzer.  
 
Fig. 4. Scatter chart showing the estimated blood glucose concentration 
against the reference blood glucose concentration, showing excellent positive 
correlation between these two data sets. 
 
Fig. 5. Clarke Error Grid of data set from 24 subjects (214 data points). 
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